证券代码：300863 证券简称：卡倍亿 公告编号：2025-075 宁波卡倍亿电气技术股份有限公司 关于 2022 年限制性股票激励计划部分限制性股票回购注销 完成暨股份变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 性股票数量合计294,000股，占回购注销前公司总股本的0.16%，涉及激励对象5 人。 限制性股票注销事宜已于2025年8月15日办理完成。 宁波卡倍亿电气技术股份有限公司（简称"公司"）于 2025 年 6 月 6 日和 和 2025 年第一次临时股东会,审议通过了《关于公司 2022 年限制性股票激励计 划第三个解除限售期解除限售条件未成就、第三个归属期归属条件未成就及回购 注销、作废部分限制性股票的议案》和《关于修订 <公司章程> 的议案》，同意回 购 2022 年限制性股票激励计划已授予但尚未解除限售的限制性股票数量合计 项说明如下： 一、股权激励计划已履行的相关审批程序 《关于公司<2022 年限制性股票激励计划（草案）>及其摘要的议案》《关于公 司<2022 年限制性股票激励计划实施考核管理办法>的议案》《 ...

证券代码：300863 证券简称：卡倍亿 公告编号：2025-075 宁波卡倍亿电气技术股份有限公司 关于 2022 年限制性股票激励计划部分限制性股票回购注销 完成暨股份变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次回购注销2022年限制性股票激励计划已授予但尚未解除限售的限制 性股票数量合计294,000股，占回购注销前公司总股本的0.16%，涉及激励对象5 人。 3、注销完成后，公司股份总数由188,469,836股减少至188,175,836股。 宁波卡倍亿电气技术股份有限公司（简称"公司"）于 2025 年 6 月 6 日和 2025 年 6 月 23 日分别召开第四届董事会第二次会议、第四届监事会第二次会议 和 2025 年第一次临时股东会,审议通过了《关于公司 2022 年限制性股票激励计 划第三个解除限售期解除限售条件未成就、第三个归属期归属条件未成就及回购 注销、作废部分限制性股票的议案》和《关于修订<公司章程>的议案》，同意回 购 2022 年限制性股票激励计划已授予但尚未解除限售的限制性股票数量合计 29 ...

Core Viewpoint - 卡倍亿 has received an administrative regulatory measure decision from the Ningbo Securities Regulatory Bureau due to non-compliance with disclosure requirements regarding shareholder equity changes [1][2] Group 1: Regulatory Actions - The Ningbo Securities Regulatory Bureau issued a decision on August 14, 2025, requiring 卡倍亿 to correct its actions and participate in regulatory discussions due to undisclosed changes in shareholder equity [1][2] - 卡倍亿's controlling shareholder increased their stake from 56.97% to 57.11% without proper announcement, violating the regulations [1][2] - The company is required to submit a written rectification report within ten working days and enhance its compliance with securities laws [2] Group 2: Previous Violations - This is not the first instance of regulatory scrutiny for 卡倍亿; the company received two warning letters in a month last year regarding its executives' trading activities [2][3] - Specific violations included short-term trading of convertible bonds by executives, which occurred within a prohibited timeframe [3] Group 3: Financial Background - 卡倍亿 was listed on the Shenzhen Stock Exchange on August 24, 2020, raising approximately 259.49 million yuan through its initial public offering [4] - The company has conducted multiple rounds of fundraising through convertible bonds, with the total amount raised across three instances reaching approximately 1.067 billion yuan [6][7]

Core Viewpoint - The company, 卡倍亿, received an administrative regulatory measure decision from the Ningbo Securities Regulatory Bureau due to non-compliance with regulations regarding shareholder equity changes [1][2]. Group 1: Regulatory Actions - 卡倍亿 was ordered to correct its actions and engage in regulatory discussions following a violation of the "Management Measures for the Acquisition of Listed Companies" [2]. - The company must submit a written rectification report within ten working days of receiving the decision [2]. - The chairman and general manager, 林光耀, along with the board secretary and deputy general manager, 秦慈, are required to attend regulatory discussions [2]. Group 2: Shareholder Changes - On May 22, 2025, 卡倍亿's controlling shareholder, 宁波新协实业集团有限公司, increased its shareholding from 76,881,000 shares to 107,633,400 shares, raising its ownership percentage from 56.97% to 57.11% [1]. - The company failed to announce this change in shareholding as required when the percentage change reached an integer multiple of 1% [1]. Group 3: Previous Regulatory Issues - This is not the first time 卡倍亿 has faced regulatory scrutiny; the company received two warning letters within a month in the previous year regarding its executives [2]. - In April 2024, two executives received warning letters for engaging in short-term trading of company bonds, violating regulations [3]. - In May 2024, the deputy general manager, 秦慈, received a warning for purchasing company stock within 30 days prior to the annual report announcement, which also constituted a regulatory violation [3]. Group 4: Company Background - 卡倍亿 was listed on the Shenzhen Stock Exchange on August 24, 2020, with an initial public offering of 13.81 million shares at a price of 18.79 yuan per share [4]. - The total amount raised from the IPO was approximately 259.49 million yuan, with a net amount of about 215.88 million yuan after deducting issuance costs [4][5]. - The company has conducted multiple rounds of fundraising through convertible bonds, raising a total of approximately 1.067 billion yuan across three fundraising events [6][7].

每经AI快讯，8月15日，卡倍亿（300863）公告，公司于2025年8月14日收到宁波证监局《行政监管措 施决定书》。控股股东宁波新协实业集团有限公司及其一致行动人林光耀、林光成、林强持股数量从 7688.1万股增加至1.08亿股，持股比例从56.97%增加至57.11%。因未就权益变动情况作出公告，违反 《上市公司收购管理办法》第十三条第三款，被采取责令改正及监管谈话的行政监管措施。公司将及时 整改，并在规定时间内提交书面整改报告。 ...

Core Viewpoint - The company received an administrative regulatory measure decision from the Ningbo Securities Regulatory Bureau due to a failure to announce changes in equity holdings, which is a violation of the relevant regulations [1] Group 1: Shareholding Changes - The controlling shareholder, Ningbo Xiexie Industrial Group Co., Ltd., along with its concerted actors Lin Guangyao, Lin Guangcheng, and Lin Qiang, increased their shareholding from 76.81 million shares to 108 million shares [1] - The shareholding percentage rose from 56.97% to 57.11% [1] Group 2: Regulatory Actions - The company was subjected to administrative regulatory measures, including a directive for correction and a regulatory discussion due to the failure to announce the equity changes [1] - The company plans to rectify the situation promptly and will submit a written rectification report within the specified timeframe [1]

证券代码：300863 证券简称：卡倍亿 公告：2025-074 宁波卡倍亿电气技术股份有限公司 关于收到宁波证监局行政监管措施决定书的公告 本公司及董事会全体成员保证公告内容真实、准确和完整,不存在任何虚假 记载、误导性陈述或者重大遗漏。 宁波卡倍亿电气技术股份有限公司(以下简称"公司")于 2025 年 8 月 14 日收到中国证券监督管理委员会宁波监管局(以下简称"宁波证监局")出具的《关 于对宁波卡倍亿电气技术股份有限公司釆取责令改正及监管谈话措施的决定》 ([2025]23 号)(以下简称"《行政监管措施决定书》"),现将相关情况公告如下: 一、行政监管措施决定书的内容 本次收到《行政监管措施决定书》事项不会影响公司正常的生产经营管理活 动，敬请广大投资者注意投资风险。 特此公告。 宁波卡倍亿电气技术股份有限公司 "宁波卡倍亿电气技术股份有限公司: 经查，你公司于 2025 年 5 月 22 日实施 2024 年度权益分派。本次权益变动 后，你公司控股股东宁波新协实业集团有限公司及其一致行动人林光耀、林光成、 林强持有"卡倍亿"的数量从 76,881,000 股增加至 107,633,400 股，合 ...

11月14日晚间，卡倍亿发布向不特定对象发行可转换公司债券募集说明书（注册稿）。据悉，公司本次 发行拟募资总额不超过5.29亿元（含本数），扣除发行费用后计划用于湖北卡倍亿生产基地项目、宁海 汽车线缆扩建项目以及汽车线缆绝缘材料改扩建项目。 而湖北卡倍亿生产基地项目的实施地麻城是湖北省具备一定汽配产业基础的区域，目前，麻城共有各类 汽配企业200余家。 卡倍亿相关负责人称："目前，公司已在宁波、上海、本溪、成都、惠州等地布局了生产基地，通过此 次在麻城进行产业布局，将弥补公司在华中地区的产能空缺，项目建设完成后公司将基本实现西南、华 中、东北、东南各主要经济带、汽车产业聚集区的战略布局规划，有助于进一步提升公司的服务能 力。" 对此，江西新能源科技职业学院新能源汽车技术研究院院长张翔在接受《证券日报》记者采访时表示， 汽车线缆产品属于关键零部件，相关企业工厂分布范围广，可以就近给客户供货，有效快速地处理相关 问题，并提供完善的售后服务，增强客户的满意度。卡倍亿此次在湖北规划新的产能基地，有助于进一 步提升企业核心竞争力。 另外，卡倍亿拟将2亿元募集资金用于宁海汽车线缆扩建项目，具体用项包括购置大拉机、多头拉丝 ...

Group 1 - Xuanbu Investment recently conducted research on a listed company, Shenyuan Biological, focusing on its strategic vision of building a world-class high-tech biotechnology company [1] - Shenyuan Biological has invested 60 million yuan to acquire a 20.48% stake in Yangzhou Shizhi Source Biotechnology Co., which specializes in innovative drug development [1] - The company is advancing several monoclonal antibody drugs, including UB-421 for HIV treatment, UB-221 for chronic spontaneous urticaria, and UB-621 for herpes simplex virus, with various stages of clinical trials ongoing [1] Group 2 - Shenyuan Biological plans to assess further investment or acquisition opportunities based on clinical trial outcomes and market conditions [1] - The company has repurchased 3,417,373 shares and intends to introduce an equity incentive plan in line with business development stages [1] - Shenyuan Biological aims to invest in innovative drug pipelines through mergers and acquisitions, focusing on core technology platforms and seeking synergistic biopharmaceutical targets [1] Group 3 - The company is collaborating with the Lanzhou Veterinary Research Institute of the Chinese Academy of Agricultural Sciences to develop two foot-and-mouth disease vaccines, expected to meet market demand for effective vaccines [1] - This investment marks a significant step in strategic alignment and a shift in business focus towards innovation opportunities in the biopharmaceutical sector [1]

Group 1 - The core point of the news is that Kabeiyi (300863) experienced a net financing purchase of 91,000 yuan on August 7, 2025, with a total financing balance of 319 million yuan, indicating a positive investor sentiment in the market [1][2][3] - Over the past three trading days, Kabeiyi has seen a cumulative net purchase of 432,620 yuan, reflecting a consistent buying trend [1] - The financing balance on August 7, 2025, accounted for 4.93% of the circulating market value, showing a slight increase from previous days [2][3] Group 2 - The financing balance increased by 0.03% on August 7, 2025, compared to the previous day, indicating a stable market condition [3] - The data shows fluctuations in net financing purchases over the past week, with the highest net purchase recorded on August 5, 2025, at 2.84 million yuan [2][3] - There were no short-selling transactions on August 7, 2025, suggesting a lack of bearish sentiment in the market [1]